Journal
NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-10853-2
Keywords
-
Categories
Funding
- iNEXT - Horizon 2020 programme of the European Commission [653706]
- German Cancer Consortium (DKTK)
- DFG [SFB807]
Ask authors/readers for more resources
The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix alpha 11 and the alpha 11-alpha 12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix alpha 12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix all that destabilizes the alpha 11-alpha 12 loop, a critical determinant for helix alpha 12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available